Serum Interleukin-19 (IL-19) levels in Acne Vulgaris patients and its correlation with the disease severity
Not Applicable
- Conditions
- Health Condition 1: L700- Acne vulgaris
- Registration Number
- CTRI/2022/11/047057
- Lead Sponsor
- Father Muller Research Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. All cases clinically diagnosed with Acne Vulgaris who are willing to participate in the study.
2. Age and sex matched volunteers willing to participate in the study.
Exclusion Criteria
1.Patient with Acne Vulgaris who have been on any systemic and topical treatment in the last two weeks.
2.Patients with other conditions where serum IL-19 will be elevated like psoriasis, atopic dermatitis and asthma.
3.Patients taking any comedogenic drugs in the previous month, pregnant or postpartum individuals.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To measure the serum IL-19 levels in Acne Vulgaris patients and in healthy controls. The study will also correlate serum IL-19 levels with the disease severity.Timepoint: 18 months
- Secondary Outcome Measures
Name Time Method To measure the serum IL-19 levels in Acne Vulgaris patients and in healthy controls. The study will also correlate serum IL-19 levels with the disease severity.Timepoint: 18 months